TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: CPX-351 Real-World Effectiveness and Safety Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Aged ≥18 years at the start of treatment of AML with Vyxeos liposomal~* Pathological diagnosis of t-AML or AML-MRC according to World Health Organization criteria (with at least 20% blasts in the peripheral blood or bone marrow)~* Patient has received at least one infusion of Vyxeos liposomal, prescribed as per the SmPC~* Patient signs an informed consent form or is included in accordance with an informed consent waiver~Exclusion Criteria:~* Treatment with Vyxeos liposomal as part of a clinical trial or managed access program~* Prior treatment intended for induction therapy of AML; only hydroxyurea is permitted for control of blood counts

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CPX-351 (Type: None): Adult patients with newly diagnosed, therapy related acute myeloid leukaemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC) who were treated in routine practice with Vyxeos liposomal in the UK.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Combination Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed stage II, III, or IV diffuse large cell lymphoma and WHO variants~  * CD20+ large B-cell lymphoma, including those with immunoblastic features~ * CD20+ thymic B-cell lymphoma~ * No evidence of indolent lymphoma~ * No mantle cell lymphomas or equivocal B-cell lymphomas that express markers of mantle cell lymphoma (e.g., cyclin D) or other subtypes~* No known lymphomatous involvement of the CNS, including the parenchyma or leptomeninges~PATIENT CHARACTERISTICS:~Age:~* Not specified~Performance status:~* CALGB 0-2~Life expectancy:~* Not specified~Hematopoietic:~* Absolute neutrophil count at least 1,000/mm3\*~* Platelet count at least 100,000/mm3\* NOTE: \* Unless due to lymphoma~Hepatic:~* Bilirubin no greater than 2.0 mg/dL\* NOTE: \* Unless due to lymphoma or Gilbert's disease~Renal:~* Creatinine no greater than 1.5 mg/dL\* NOTE: \* Unless due to lymphoma~Cardiovascular:~* LVEF greater than 45%~* No ischemic heart disease~* No myocardial infarction or congestive heart failure within the past year~Other:~* HIV negative~* Not pregnant or nursing~* Fertile patients must use effective contraception~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* Not specified~Chemotherapy:~* No prior cytotoxic chemotherapy~* No other concurrent chemotherapy~Endocrine therapy:~* Prior short-course of glucocorticoids allowed~* No concurrent hormones except for non-disease-related conditions (e.g., insulin for diabetes)~* No concurrent steroids except for adrenal failure~* No concurrent dexamethasone or other steroidal antiemetics~Radiotherapy:~* Prior limited-field radiotherapy allowed~Surgery:~* Not specified

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- EPOCH-Rituximab (Type: EXPERIMENTAL): Addition of monoclonal antibody therapy to chemotherapy for treatment of pts with aggressive CD20+ NHL

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Prevention of Drug Induced Ototoxicity in Peritoneal Dialysis Patients by N-Acetylcysteine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* End-stage renal disease~* Undergoing continuous ambulatory peritoneal dialysis as a renal replacement therapy~* Clinical diagnosis of a peritonitis episode in a continuous ambulatory peritoneal dialysis patient~* Developing the first continuous ambulatory peritoneal dialysis related peritonitis episode~Exclusion Criteria:~* Being treated with aminoglycoside antibiotics and vancomycine within the previous 3 months~* Detection of mechanical occlusion of external ear~* Having signs of disturbed integrity of tympanic membrane on otoscopy or tympanometry~* History of a continuous ambulatory peritoneal dialysis related peritonitis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- N-acetylcysteine (Type: EXPERIMENTAL): N-acetylcysteine 600 mg twice daily + vancomycine and/or amikacin
- Controls (Type: NO_INTERVENTION): Vancomycine and/or amikacin alone

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of 90Y Zevalin in Nonmyeloablative Transplantation for Lymphoid Malignancies

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients in relapse or considered at high risk for relapse or refractory CD-20-positive B-cell NHL or CLL. Patients considered for high risk of relapse are patients who do not achieve complete response (CR) with frontline chemotherapy, CLL is Richter's and CLL with high risk chromosomal abnormalities.~2. Measurable disease.~3. Age 18-70 years, expected survival \>/= 3 months, performance status 0 to 2.~4. Availability of a matched related donor.~5. \</+ 50% bone marrow involvement.~6. CLL with \</+ 10,000 circulating lymphocytes.~7. Availability of a matched related or unrelated donor.~Exclusion Criteria:~1. Prior myeloablative therapies or radioimmunotherapy.~2. Prior external beam radiation therapy to \>25% of active bone marrow.~3. Prior therapy with 90Y Zevalin or Campath.~4. CNS lymphoma, HIV, HTLV-1 positivity, some creatinine \>1.6 mg/dl or serum bilirubin \>1.5 mg/dl.~5. Pregnancy or lactation.~6. Symptomatic pulmonary or cardiac disease.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- 90Y Zevalin in ASCT (Type: EXPERIMENTAL): Allogeneic Stem Cell (AST) Transplantation with 90Y Zevalin/Cyclophosphamide/Fludarabine as a preparative regimen.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Semi-occluded Vocal Tract Therapy on the Phonation of Children With Vocal Fold Nodules

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* children aged between 6 and 12 years (primary school)~* diagnosed with vocal fold nodules by an otorhinolaryngologist and speech-language pathologist experienced in voice diagnostics.~Exclusion Criteria:~* nasal or ear diseases~* neurological disorders

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 12 Years
- Healthy Volunteers: f

Study Arms:
- Experimental group 1 - Straw Phonation (Type: EXPERIMENTAL): Short-term intensive voice therapy program of one week (3 hours a day for 4 consecutive days): straw phonation and vocal hygiene recommendations
- Experimental group 2 - Resonant Voice Therapy (Type: EXPERIMENTAL): Short-term intensive voice therapy program of one week (3 hours a day for 4 consecutive days): resonant voice therapy and vocal hygiene recommendations
- Control group (Type: SHAM_COMPARATOR): Short-term intensive voice therapy program of one week (3 hours a day for 4 consecutive days): vocal hygiene recommendations

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Continuous Administration of Oral Contraceptive, Primary Dysmenorrhea

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy women ages 18-35 with a history of PD (onset \< 3 years after menarche).~* Subjects must have had regular (25-31 day) menstrual cycles for the three month period preceding enrollment, with symptoms of moderate to severe PD during those cycles.~Exclusion Criteria:~* Patients who have contraindications to OCP therapy.~* Known or suspected secondary dysmenorrhea (major abdominal or pelvic surgery, endometriosis, pelvic inflammatory disease (PID), ovarian cysts, pathological vaginal secretion, chronic abdominal pain, inflammatory bowel disease, irritable bowel syndrome).~* Concomitant treatment with oral contraceptives, GnRH agonists and antagonists, antiandrogens, gonadotropins, anti-obesity drugs.~* The use of contraceptive implants, injectable contraceptives or intrauterine devices. The washout period on all these medications will be 3 months.~* Migraines, depression requiring hospitalization or associated with suicidal ideation during previous estrogen or ocp use.~* Known or suspected hypersensitivity to trial drug.~* Patients enrolled simultaneously into other investigative studies that require meds.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 35 Years
- Healthy Volunteers: t

Study Arms:
- study group (CCOCP) (Type: EXPERIMENTAL): treatment with monophasic oral contraceptive (gestodene 0,075 mg /ethinyl estradiol 20 mcg) for 168 continuous days through six cycles
- control group (traditional OCP) (Type: ACTIVE_COMPARATOR): treatment with monophasic oral contraceptive (gestodene 0,075 mg /ethinyl estradiol 20 mcg) for traditional (21 active days/7 inactive days) regimen through six cycles.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Colchicine Randomized Double-Blind Controlled Crossover Study in Behcet's Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient's who fulfilled the International Criteria for Behcet's Disease.~Exclusion Criteria:~* major organ involvement~* Hypersensitivity reaction

- Gender: ALL
- Minimum Age: 14 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Colchicine (Type: ACTIVE_COMPARATOR): Patients who received Colchicine and went on placebo after 4 months
- Placebo (Type: PLACEBO_COMPARATOR): Patients who received placebo and went on Colchicine after 4 months

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Smoking Termination Opportunity for inPatients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Smoker of at least 10 cigarettes per day on average over the past 12 months~* Inpatient with an anticipation admission of at least one day~* Willingness to quit smoking~* Aged between 20 and 75 years~* A plan of discharge to go home~* Acute hospital admission with cardiovascular, cerebrovascular, peripheral vascular diseases or airways (asthma and/or Chronic Obstructive Pulmonary disease~Exclusion Criteria:~* Subject preference to use an alternative pharmacotherapy for smoking cessation~* Respiratory patient being considered for home oxygen~* Pregnancy~* Breast feeding~* Acute or pre-existing severe psychiatric illnesses~* Past history of psychosis or suicidal ideation~* Renal impairment with creatinine clearance \<30ml/min

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Champix plus counselling (Type: EXPERIMENTAL): varenicline tartrate will be initiated whilst subjects are inpatients with the standard MIMS dosing schedule (including period of titration). In combination with Quit SA (5A) telephone counselling service
- counselling alone (Type: ACTIVE_COMPARATOR): 5A counselling via Quit SA (quitline) telephone counselling service. (maximum 8 phone calls per subject within a 3 month period).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Fluzoparib Given in Combination With Apatinib in Ovarian or Breast Cancer Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.~* Life expectancy of more than 12 weeks.~* Histologically or cytologically confirmed high-grade papillary-serous epithelial ovarian cancer，primary peritoneal, or fallopian tube cancers; subjects with a known deleterious breast cancer gene (BRCA) mutation and any other high-grade histology are also eligible. Subjects should have platinum-sensitive disease, where platinum-sensitive disease is defined as having had a \> 6 month interval since last receiving platinum therapy prior to disease recurrence. Additionally, subjects with histologically or cytologically confirmed triple negative breast cancer (TNBC）, that is locally advanced or metastatic, are also eligible.~* Prior therapy：subjects with ovarian cancer，primary peritoneal, or fallopian tube cancers have received only 2 lines of platinum-based chemotherapies, and TNBC patients have received only 1 line of standard chemotherapy. Each prior chemotherapy must be given for at least 2 cycles.~* At least one measurable lesion that can be accurately assessed by imaging (CT/MRI) at baseline~* Subjects who have overall good overall general condition.~* Signed informed consent.~Exclusion Criteria:~* Subjects who received any previous treatment with any PARP inhibitors.~* Subjects who received any previous treatment with any VEGFR inhibitors.~* Less than 4 weeks from the last clinical trial.~* Less than 4 weeks from the last radiotherapy, chemotherapy, surgery, hormone treatment and target therapy.~* Unstable or uncontrolled hypertension.~* Subjects that are unable to swallow, or dysfunction of gastrointestinal absorption.~* Subjects with brain metastases.~* Subjects with uncontrolled hypokalemia and hypomagnesemia before study entry.~* Subjects with a known hypersensitivity to fluzoparib, apatinib or any of the excipients of the products.~* Ongoing infection (determined by investigator).~* History of immunodeficiency, including HIV-positive, suffering from other acquired, congenital immunodeficiency disease, or history of organ transplantation.~* Pregnant or breast-feeding women.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Fluzoparib + Apatinib (Type: EXPERIMENTAL): Fluzoparib and apatinib will be separately administered to patients on the 1st and 4th day, respectively. Then from the 7th day they are administered continuously and orally in combination, 28 days per cycle, until disease progression or unacceptable toxicity.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Prospective Study of HBV Immunity and HBV Vaccination in Patients With NAFLD in Canada

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Subjects 18-60 years of age, who provide signed informed consent~* Diagnosis of NAFLD/NASH according to expert assessment (by imaging, TE, abnormal lab tests and/or liver biopsy)~* No evidence of prior infection or immunity to hepatitis B (negative HBsAg, anti-HBs, anti-HBc).~Exclusion Criteria:~* Subjects \< 18 years of age,~* Subjects who refused vaccination~* Have documented immunity / prior exposure to hepatitis B (i.e., positive for ant-HBs, anti-HBc, HBsAg)~* Pregnancy~* HIV-positive~* Decompensated cirrhosis (i.e., Child-Pugh Class B or C) due to impact on immune response.~* Subjects \>60 y will be excluded, due to effect of age and reduced response to HBV vaccination.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Relative Bioavailability Study to Assess Two Solid Formulations Compared to an Oral Solution of AZD3293 in Healthy Male and Non-Fertile Female Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Provision of signed, written, and dated informed consent prior to any study-specific procedures~2. Healthy subjects must be able to understand and be willing to comply with study procedures, restrictions, and requirements.~3. Male and non-fertile female healthy subjects, aged 18 to 55 years~4. Body weight ≥50 to ≤100 kg and body mass index (BMI) ≥19 to ≤30 kg/m2~5. Clinically normal findings on physical examination in relation to age, as judged by the Investigator~Exclusion Criteria:~1. History of any clinically significant disease or disorder which, in the opinion of the Investigator, may either put the subject at risk because of participation in the study, or influence the results or the subject's ability to participate in the study~2. History or presence of gastrointestinal, hepatic or renal disease or any other condition known to interfere with absorption, distribution, metabolism or excretion of drugs~3. History of previous or ongoing psychiatric disease/condition including psychosis, affective disorder, anxiety disorder, borderline state and personality disorder according to the criteria in the Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM IV), as assessed by the Mini-International Neuropsychiatric Interview (MINI)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- AZD3293 oral solution (Type: EXPERIMENTAL): single doses in random order in 3 study periods for each subject (Day 1 or Day 8 or Day 15)
- AZD3293 tablet formulation A (Type: EXPERIMENTAL): single doses in random order in 3 study periods for each subject (Day 1 or Day 8 or Day 15)
- AZD3293 tablet formulation B (Type: EXPERIMENTAL): single doses in random order in 3 study periods for each subject (Day 1 or Day 8 or Day 15)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Safety and Efficacy of Artemether-Lumefantrine Tablets in African Infants and Children With Uncomplicated P. Falciparum Malaria

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* male or female weighing ≥ 5kg and ≤ 25kg~* P. falciparum parasitemia between 1,000 and 100,000 parasites/mm3~* with confirmed diagnosis of uncomplicated malaria caused P. falciparum parasite~Exclusion Criteria:~* complicated malaria~* ingestion of various antimalarial drugs, or other drugs influencing cardiac function in the previous 4 weeks before study entry to 8 weeks~* severe anaemia~* severe malnutrition~* malaria due to other than P. falciparum~Other protocol-defined inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: None

Study Arms:
- 1 (Type: EXPERIMENTAL): Artemether-lumefantrine

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Use of Sugammadex Administered at 5 Minutes After Administration of 1.2 mg/kg Esmeron® (19.4.205)(P05942)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* ASA 1 - 2 between the ages of 18 and 64, inclusive~* Scheduled for surgical procedures with an anticipated duration of anesthesia of at least 90 minutes, without further need for muscle relaxation other than for intubation~* Scheduled for surgery in supine position~* Given written informed consent~Exclusion Criteria:~* Subjects in whom a difficult intubation because of anatomical malformations was expected~* Subjects known or suspected to have neuromuscular disorders impairing neuromuscular block (NMB) and/or significant renal dysfunction~* Subjects known or suspected to have a (family) history of malignant hyperthermia~* Subjects known or suspected to have an allergy to narcotics, muscle relaxants or other medication used during general anesthesia~* Subjects receiving medication known to interfere with neuromuscular blocking agents such as anticonvulsants and Mg2+~* Subjects who had already participated in CT 19.4.205~* Subjects who had participated in another clinical trial, not pre-approved by NV Organon, within 30 days of entering into CT 19.4.205~* Female subjects who are pregnant: in females pregnancy was to be excluded both from medical history and by an hCG test within 24 hours before surgery except in females who were not of childbearing potential i.e. at least 2 years postmenopausal or underwent tubal ligation or an hysterectomy~* Females of childbearing potential not using an acceptable method of birth control: condom or diaphragm with spermicide, vasectomized partner (\>6 months), IUD, abstinence~* Subjects giving breast-feeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: PLACEBO_COMPARATOR): rocuronium + 16.0 mg/kg Org 25969
- 2 (Type: EXPERIMENTAL): rocuronium + 2.0 mg/kg Org 25969
- 3 (Type: EXPERIMENTAL): rocuronium + 4.0 mg/kg Org 25969
- 4 (Type: EXPERIMENTAL): rocuronium + 8.0 mg/kg Org 25969
- 5 (Type: EXPERIMENTAL): rocuronium + 12.0 mg/kg Org 25969

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete